Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8069437 | 1.00 | PDCD1 (0.38) | PDCD1CD274SYKHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2919569 | 0.99 | PDCD1 (0.37) | PDCD1CD274SYKHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2912614 | 0.99 | PDCD1 (0.37) | PDCD1CD274SYKHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2912612 | 0.99 | PDCD1 (0.37) | PDCD1CD274SYKHCRTR1HCRTR2 | |
| SCHEMBL7915999 | 0.87 | HCRTR1 (0.34) | HCRTR1HCRTR2CHRM3 | |
| SCHEMBL3377163 | 0.82 | SYK (0.36) | PDCD1CD274SYKHCRTR1HCRTR2 | |
| SCHEMBL8027521 | 0.81 | PDE4D (0.52) | CD274HCRTR1HCRTR2PDE4BPDE4D | |
| Acetic Acid SCHEMBL3466976 | 0.80 | PDE4D (0.50) | CD274HCRTR1HCRTR2PDE4BPDE4D | |
| SCHEMBL3466400 | 0.76 | PDE4D (0.50) | PDCD1CD274HCRTR1HCRTR2PDE4B | |
| SCHEMBL3466397 | 0.76 | PDE4D (0.50) | PDCD1CD274HCRTR1HCRTR2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | PDCD1 852/4885CD274 1658/4885SYK 1271/4885 |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4B, PDE4A, PDE3B | PDCD1 1270/4885CD274 1971/4885SYK 881/4885 |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | PDCD1 852/4885CD274 1658/4885SYK 1271/4885 |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | PDCD1 852/4885CD274 1658/4885SYK 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.